• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Mucopolysaccharidosis I

Mucopolysaccharidosis I - 57 Studies Found

Active, not recruiting : Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study)
:
  • Morquio A Syndrome
  • Mucopolysaccharidosis IV A

: 2014-08-01
Withdrawn : Dynamic Gait Analysis in Children With Mucopolysaccharidosis Type IVa
:
  • Mucopolysaccharidosis IV
  • Morquio A Disease

: 2014-05-28
Completed : Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
:
  • Morquio Syndrome A
  • Maroteaux Lamy Syndrome
  • MPS IVA
  • Morquio Syndrome

: 2013-08-08
Completed : A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
:
  • Mucopolysaccharidosis IV Type A
  • Morquio A Syndrome
  • : 2014-10-28
    : Drug: Vimizim® (elosulfase alfa) Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
Completed : Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
:
  • Mucopolysaccharidosis IV A
  • Morquio A Syndrome
  • Drug: BMN 110 - Weekly

Terminated : A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
:
  • MPS IV A
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome

  • : 2008-11-06
Completed : A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
: MPS IV A
: 2011-01-10
:
  • Drug: BMN 110 Weekly BMN 110 W

Approved for marketing : BMN 110 US Expanded Access Program
:
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome
  • MPS IVA

  • : 2013-05-15
    : Drug: BMN 110
Terminated : A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
:
  • MPS IV A
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome

  • : 2010-10-28
    : Drug: BMN 110 Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.